Figure 3
![Figure 3. OS and PFS in 26 patients with good risk features. Patients allografted since 2001 with chemosensitive disease and good performance status at the time of allogeneic HSCT show a favorable outcome (overall survival [OS], solid line; progression-free survival [PFS], dotted line).](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/114/10/10.1182_blood-2008-11-189399/4/zh89990939950003.jpeg?Expires=1735573239&Signature=fsCPoFrBmPbSMLMoBoqoWXGkgaYFT-4Jq1PmmWPHKerluNnysr~PfwND6gydhcYOLSPNtr8AxsMgz0CDR1u0tmvfA7WGAg4CggBIVhUwCPVaPysDjrPhp~Np5T9McbLAD1yZNHacqY-5zo3lD~mB03WS4Wqov1Nj9UCoMMFm3aqByZA9ZAXfIvtWwuGBiyeuFjHk1oXxQReeTHvBgvmZMWYd8iEX6Z8KbNSBXji5InFoDfR7uhxy~6fkbncR0IjbHYPS0I58WKMGsCxupXUsI84ORI7g-T6PBuZzYSRywZZ3hdk9oPPnog82ns8m466NyGarxtV69GRlQBgd53lYWg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
OS and PFS in 26 patients with good risk features. Patients allografted since 2001 with chemosensitive disease and good performance status at the time of allogeneic HSCT show a favorable outcome (overall survival [OS], solid line; progression-free survival [PFS], dotted line).
